Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016;6(1):49-67.
doi: 10.15171/bi.2016.07. Epub 2016 Mar 30.

Advanced Drug Delivery and Targeting Technologies for the Ocular Diseases

Affiliations
Free PMC article
Review

Advanced Drug Delivery and Targeting Technologies for the Ocular Diseases

Jaleh Barar et al. Bioimpacts. .
Free PMC article

Abstract

Introduction: Ocular targeted therapy has enormously been advanced by implementation of new methods of drug delivery and targeting using implantable drug delivery systems (DDSs) or devices (DDDs), stimuli-responsive advanced biomaterials, multimodal nanomedicines, cell therapy modalities and medical bioMEMs. These technologies tackle several ocular diseases such as inflammation-based diseases (e.g., scleritis, keratitis, uveitis, iritis, conjunctivitis, chorioretinitis, choroiditis, retinitis, retinochoroiditis), ocular hypertension and neuropathy, age-related macular degeneration and mucopolysaccharidosis (MPS) due to accumulation of glycosaminoglycans (GAGs). Such therapies appear to provide ultimate treatments, even though much more effective, yet biocompatible, noninvasive therapies are needed to control some disabling ocular diseases/disorders.

Methods: In the current study, we have reviewed and discussed recent advancements on ocular targeted therapies.

Results: On the ground that the pharmacokinetic and pharmacodynamic analyses of ophthalmic drugs need special techniques, most of ocular DDSs/devices developments have been designed to localized therapy within the eye. Application of advanced DDSs such as Subconjunctival insert/implants (e.g., latanoprost implant, Gamunex-C), episcleral implant (e.g., LX201), cationic emulsions (e.g., Cationorm™, Vekacia™, Cyclokat™), intac/punctal plug DDSs (latanoprost punctal plug delivery system, L-PPDS), and intravitreal implants (I-vitaion™, NT-501, NT- 503, MicroPump, Thethadur, IB-20089 Verisome™, Cortiject, DE-102, Retisert™, Iluvein™ and Ozurdex™) have significantly improved the treatment of ocular diseases. However, most of these DDSs/devices are applied invasively and even need surgical procedures. Of these, use of de novo technologies such as advanced stimuli-responsive nanomaterials, multimodal nanosystems (NSs)/nanoconjugates (NCs), biomacromolecualr scaffolds, and bioengineered cell therapies need to be further advanced to get better compliance and higher clinical impacts.

Conclusion: Despite mankind successful battle on ocular diseases, our challenge will continue to battle the ocular disease that happen with aging. Yet, we need to understand the molecular aspects of eye diseases in a holistic way and develop ultimate treatment protocols preferably as non-invasive systems.

Keywords: Eye diseases; Intraocular drug delivery; Ocular barriers; Ocular drug targeting; Ocular pharmacotherapy; Ophthalmic implants; Ophthalmology; Targeted therapy.

Figures

Fig. 1
Fig. 1
Fig. 2
Fig. 2
Fig. 3
Fig. 3
Fig. 4
Fig. 4
Fig. 5
Fig. 5
Fig. 6
Fig. 6
Fig. 7
Fig. 7
Fig. 8
Fig. 8

Similar articles

See all similar articles

Cited by 22 articles

See all "Cited by" articles

References

    1. Cholkar K, Patel SP, Vadlapudi AD, Mitra AK. Novel strategies for anterior segment ocular drug delivery. J Ocul Pharmacol Ther. 2013;29:106–23. doi: 10.1089/jop.2012.0200. - DOI - PMC - PubMed
    1. Barar J, Asadi M, Mortazavi-Tabatabaei SA, Omidi Y. Ocular drug delivery: impact of in vitro cell culture models. Journal of Ophthalmic & Vision Research. 2009;4:238–52. - PMC - PubMed
    1. Willoughby CE, Ponzin D, Ferrari S, Lobo A, Landau K, Omidi Y. Anatomy and physiology of the human eye: effects of mucopolysaccharidoses disease on structure and function–a review. Clinical & Experimental Ophthalmology. 2010;38:2–11. - PubMed
    1. Kompella UB, Kadam RS, Lee VH. Recent advances in ophthalmic drug delivery. Ther Deliv. 2010;1:435–56. doi: 10.4155/TDE.10.40. - DOI - PMC - PubMed
    1. Boddu SH, Gunda S, Earla R, Mitra AK. Ocular microdialysis: a continuous sampling technique to study pharmacokinetics and pharmacodynamics in the eye. Bioanalysis. 2010;2:487–507. doi: 10.4155/bio.10.2. - DOI - PubMed

LinkOut - more resources

Feedback